Ozagrel

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Ozagrel
Accession Number
DB12017
Type
Small Molecule
Groups
Investigational
Description

Ozagrel has been used in trials studying the treatment of Dry Eye Syndromes.

Structure
Thumb
Synonyms
Not Available
External IDs
KCT-0809
Product Ingredients
IngredientUNIICASInChI Key
Ozagrel HydrochlorideW222U960HS78712-43-3CWKFWBJJNNPGAM-IPZCTEOASA-N
Ozagrel Sodium4X5577N3ET189224-26-8NCNYJCOBUTXCBR-IPZCTEOASA-M
Categories
UNII
L256JB984D
CAS number
82571-53-7
Weight
Average: 228.251
Monoisotopic: 228.089877634
Chemical Formula
C13H12N2O2
InChI Key
SHZKQBHERIJWAO-AATRIKPKSA-N
InChI
InChI=1S/C13H12N2O2/c16-13(17)6-5-11-1-3-12(4-2-11)9-15-8-7-14-10-15/h1-8,10H,9H2,(H,16,17)/b6-5+
IUPAC Name
(2E)-3-{4-[(1H-imidazol-1-yl)methyl]phenyl}prop-2-enoic acid
SMILES
OC(=O)\C=C\C1=CC=C(CN2C=CN=C2)C=C1

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Ozagrel.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Ozagrel.Experimental
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Ozagrel.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Ozagrel.Experimental, Illicit
AbciximabOzagrel may increase the anticoagulant activities of Abciximab.Approved
AcenocoumarolOzagrel may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Ozagrel.Approved, Vet Approved
AloxiprinThe risk or severity of adverse effects can be increased when Aloxiprin is combined with Ozagrel.Experimental
AlprostadilAlprostadil may increase the anticoagulant activities of Ozagrel.Approved, Investigational
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Ozagrel.Approved
AmphetamineAmphetamine may decrease the sedative activities of Ozagrel.Approved, Illicit, Investigational
AnagrelideAnagrelide may increase the anticoagulant activities of Ozagrel.Approved
AncrodOzagrel may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideAndrographolide may increase the anticoagulant activities of Ozagrel.Investigational
Antithrombin III humanOzagrel may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanOzagrel may increase the anticoagulant activities of Apixaban.Approved
AprotininThe therapeutic efficacy of Ozagrel can be decreased when used in combination with Aprotinin.Approved, Investigational, Withdrawn
ArdeparinOzagrel may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanOzagrel may increase the anticoagulant activities of Argatroban.Approved, Investigational
AzelastineAzelastine may increase the anticoagulant activities of Ozagrel.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Ozagrel.Approved, Investigational
BecaplerminOzagrel may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BenzphetamineBenzphetamine may decrease the sedative activities of Ozagrel.Approved, Illicit
Benzylpenicilloyl PolylysineOzagrel may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BeraprostBeraprost may increase the anticoagulant activities of Ozagrel.Investigational
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Ozagrel.Approved, Investigational
BivalirudinOzagrel may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BuflomedilBuflomedil may increase the anticoagulant activities of Ozagrel.Experimental
ButylphthalideButylphthalide may increase the anticoagulant activities of Ozagrel.Investigational
CangrelorCangrelor may increase the anticoagulant activities of Ozagrel.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Ozagrel.Experimental, Investigational
CertoparinOzagrel may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChlorphentermineChlorphentermine may decrease the sedative activities of Ozagrel.Illicit, Withdrawn
CilostazolCilostazol may increase the anticoagulant activities of Ozagrel.Approved, Investigational
Citric AcidOzagrel may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClopidogrelClopidogrel may increase the anticoagulant activities of Ozagrel.Approved
CloricromenCloricromen may increase the anticoagulant activities of Ozagrel.Experimental
Dabigatran etexilateOzagrel may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinOzagrel may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidOzagrel may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanOzagrel may increase the anticoagulant activities of Darexaban.Investigational
DefibrotideDefibrotide may increase the anticoagulant activities of Ozagrel.Approved, Investigational
DersalazineThe risk or severity of adverse effects can be increased when Dersalazine is combined with Ozagrel.Investigational
DesirudinOzagrel may increase the anticoagulant activities of Desirudin.Approved
DextranOzagrel may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DextroamphetamineDextroamphetamine may decrease the sedative activities of Ozagrel.Approved, Illicit
DicoumarolOzagrel may increase the anticoagulant activities of Dicoumarol.Approved
DiethylpropionDiethylpropion may decrease the sedative activities of Ozagrel.Approved, Illicit
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Ozagrel.Approved, Investigational
DipyridamoleDipyridamole may increase the anticoagulant activities of Ozagrel.Approved
Edetic AcidOzagrel may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanOzagrel may increase the anticoagulant activities of Edoxaban.Approved
EnoxaparinOzagrel may increase the anticoagulant activities of Enoxaparin.Approved
EpinastineEpinastine may increase the anticoagulant activities of Ozagrel.Approved, Investigational
EplivanserinEplivanserin may increase the anticoagulant activities of Ozagrel.Investigational
eplivanserineeplivanserine may increase the anticoagulant activities of Ozagrel.Investigational
EpoprostenolEpoprostenol may increase the anticoagulant activities of Ozagrel.Approved
EptifibatideEptifibatide may increase the anticoagulant activities of Ozagrel.Approved, Investigational
Ethyl biscoumacetateOzagrel may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ferulic acidOzagrel may increase the anticoagulant activities of Ferulic acid.Experimental
FluindioneOzagrel may increase the anticoagulant activities of Fluindione.Approved, Investigational
FondaparinuxOzagrel may increase the anticoagulant activities of Fondaparinux.Approved, Investigational
Fondaparinux sodiumOzagrel may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
GabexateOzagrel may increase the anticoagulant activities of Gabexate.Investigational
GepefrineGepefrine may decrease the sedative activities of Ozagrel.Experimental
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Ozagrel.Experimental
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Ozagrel.Experimental
HeparinOzagrel may increase the anticoagulant activities of Heparin.Approved, Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Ozagrel.Approved, Investigational
HydroxyamphetamineHydroxyamphetamine may decrease the sedative activities of Ozagrel.Approved
HydroxytyrosolHydroxytyrosol may increase the anticoagulant activities of Ozagrel.Investigational
IbudilastIbudilast may increase the anticoagulant activities of Ozagrel.Approved, Investigational
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Ozagrel.Approved, Investigational, Nutraceutical
IdraparinuxOzagrel may increase the anticoagulant activities of Idraparinux.Investigational
IfenprodilIfenprodil may increase the anticoagulant activities of Ozagrel.Approved, Investigational, Withdrawn
IfetrobanIfetroban may increase the anticoagulant activities of Ozagrel.Investigational
IloprostIloprost may increase the anticoagulant activities of Ozagrel.Approved, Investigational
IndobufenIndobufen may increase the anticoagulant activities of Ozagrel.Investigational
Iofetamine I-123Iofetamine I-123 may decrease the sedative activities of Ozagrel.Approved
KetanserinKetanserin may increase the anticoagulant activities of Ozagrel.Investigational
LepirudinOzagrel may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanOzagrel may increase the anticoagulant activities of Letaxaban.Investigational
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Ozagrel.Approved, Investigational
LinsidomineLinsidomine may increase the anticoagulant activities of Ozagrel.Experimental
LisdexamfetamineLisdexamfetamine may decrease the sedative activities of Ozagrel.Approved, Investigational
MelagatranOzagrel may increase the anticoagulant activities of Melagatran.Experimental
MephedroneMephedrone may decrease the sedative activities of Ozagrel.Investigational
MephentermineMephentermine may decrease the sedative activities of Ozagrel.Approved
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Ozagrel.Approved
MethamphetamineMethamphetamine may decrease the sedative activities of Ozagrel.Approved, Illicit
MethoxyphenamineMethoxyphenamine may decrease the sedative activities of Ozagrel.Experimental
Methyl salicylateThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Ozagrel.Approved, Vet Approved
MidomafetamineMidomafetamine may decrease the sedative activities of Ozagrel.Experimental, Illicit, Investigational
MilrinoneMilrinone may increase the anticoagulant activities of Ozagrel.Approved
MMDAMMDA may decrease the sedative activities of Ozagrel.Experimental, Illicit
NadroparinOzagrel may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatOzagrel may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftopidilNaftopidil may increase the anticoagulant activities of Ozagrel.Investigational
NimesulideNimesulide may increase the anticoagulant activities of Ozagrel.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Ozagrel.Investigational
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Ozagrel.Approved
OtamixabanOzagrel may increase the anticoagulant activities of Otamixaban.Investigational
Pentaerythritol TetranitrateOzagrel may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateOzagrel may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PentoxifyllinePentoxifylline may increase the anticoagulant activities of Ozagrel.Approved, Investigational
PhenindioneOzagrel may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonOzagrel may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenterminePhentermine may decrease the sedative activities of Ozagrel.Approved, Illicit
Phenyl aminosalicylateThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Ozagrel.Approved
PicotamidePicotamide may increase the anticoagulant activities of Ozagrel.Experimental
PrasugrelPrasugrel may increase the anticoagulant activities of Ozagrel.Approved
Protein COzagrel may increase the anticoagulant activities of Protein C.Approved
Protein S humanOzagrel may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeOzagrel may increase the anticoagulant activities of Protocatechualdehyde.Approved
PseudoephedrinePseudoephedrine may decrease the sedative activities of Ozagrel.Approved
RamatrobanRamatroban may increase the anticoagulant activities of Ozagrel.Investigational
RelcovaptanRelcovaptan may increase the anticoagulant activities of Ozagrel.Investigational
ResveratrolResveratrol may increase the anticoagulant activities of Ozagrel.Approved, Experimental, Investigational
ReviparinOzagrel may increase the anticoagulant activities of Reviparin.Approved, Investigational
RidogrelRidogrel may increase the anticoagulant activities of Ozagrel.Approved
RitobegronRitobegron may decrease the sedative activities of Ozagrel.Investigational
RivaroxabanOzagrel may increase the anticoagulant activities of Rivaroxaban.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Ozagrel.Approved, Investigational, Vet Approved
SarpogrelateSarpogrelate may increase the anticoagulant activities of Ozagrel.Investigational
SevofluraneSevoflurane may increase the anticoagulant activities of Ozagrel.Approved, Vet Approved
SRT501SRT501 may increase the anticoagulant activities of Ozagrel.Investigational
SulodexideOzagrel may increase the anticoagulant activities of Sulodexide.Approved, Investigational
TesmilifeneTesmilifene may increase the anticoagulant activities of Ozagrel.Investigational
TicagrelorTicagrelor may increase the anticoagulant activities of Ozagrel.Approved
TiclopidineTiclopidine may increase the anticoagulant activities of Ozagrel.Approved
TirofibanTirofiban may increase the anticoagulant activities of Ozagrel.Approved
TranilastTranilast may increase the anticoagulant activities of Ozagrel.Approved, Investigational
TrapidilTrapidil may increase the anticoagulant activities of Ozagrel.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Ozagrel is combined with Treprostinil.Approved, Investigational
TriflusalTriflusal may increase the anticoagulant activities of Ozagrel.Approved, Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Ozagrel.Approved
TroxerutinOzagrel may increase the anticoagulant activities of Troxerutin.Investigational
VorapaxarVorapaxar may increase the anticoagulant activities of Ozagrel.Approved
WarfarinOzagrel may increase the anticoagulant activities of Warfarin.Approved
XimelagatranOzagrel may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
5282440
PubChem Substance
347828334
ChemSpider
4445594
BindingDB
50017896
ChEBI
134938
ChEMBL
CHEMBL11662
Wikipedia
Ozagrel

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedNot AvailableDry Eye Syndromes1
2CompletedTreatmentDry Eye Syndromes3
3CompletedNot AvailableDry Eye With Sjögren's Syndrome2
3TerminatedNot AvailableDry Eye With Sjögren's Syndrome1
4CompletedTreatmentCerebral Infarctions1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.424 mg/mLALOGPS
logP1.79ALOGPS
logP1.19ChemAxon
logS-2.7ALOGPS
pKa (Strongest Acidic)4.21ChemAxon
pKa (Strongest Basic)6.75ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area55.12 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity65.52 m3·mol-1ChemAxon
Polarizability23.89 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-03di-0930000000-29afc6ddb6054bfc795c
MS/MS Spectrum - , positiveLC-MS/MSsplash10-03di-0920000000-6dcd8086c8924bc1988e

Taxonomy

Description
This compound belongs to the class of organic compounds known as cinnamic acids. These are organic aromatic compounds containing a benzene and a carboxylic acid group forming 3-phenylprop-2-enoic acid.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Cinnamic acids and derivatives
Sub Class
Cinnamic acids
Direct Parent
Cinnamic acids
Alternative Parents
Styrenes / Imidazolyl carboxylic acids and derivatives / N-substituted imidazoles / Heteroaromatic compounds / Monocarboxylic acids and derivatives / Carboxylic acids / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Organic oxides
show 2 more
Substituents
Cinnamic acid / Imidazolyl carboxylic acid derivative / Styrene / Monocyclic benzene moiety / N-substituted imidazole / Benzenoid / Azole / Imidazole / Heteroaromatic compound / Carboxylic acid derivative
show 13 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 15:11 / Updated on May 02, 2018 01:39